New study aims to sharpen breast cancer detection tech
NCT ID NCT06636539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects contrast-enhanced mammogram images from 75 women aged 35+ who have a suspicious breast finding. The images will be used to improve software for future breast screening. Participants undergo standard diagnostic imaging or biopsy, but the study itself does not test a new treatment or provide direct benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject is female of any race and ethnicity. * Subject is at least 35 years old * Subject has a suspicious finding or breast abnormality on a screening or diagnostic mammogram and is indicated for a diagnostic exam or a biopsy procedure. * Subject is able to read, understand, and sign the study-specific informed consent form (ICF) after the nature of the study has been fully explained to them. Exclusion Criteria: * Subject is unable or unwilling to undergo informed consent or subject who requires a Legally Authorized Representative (LAR) for Informed Consent. * Subject has breast implants, cardiac pacemakers, nipple piercings, or IV ports in the mammography field of view in the breast of interest. * Subject has had an interventional procedure in the same breast as the suspicious finding within the last six (6) months * Subject is pregnant or presumed to be pregnant. * Subject is breastfeeding. * Subject is actively being treated for cancer of any type with chemotherapy * Subject is suspected to be at risk of complications from the iodinated contrast agent. These include contra-indications of standard iodinated contrast agents, such as the subject having renal insufficiency) and the subject being on dialysis. * Subject has had a prior reaction to iodinated contrast; thus, a known allergy to iodinated contrast. * Subject has had a prior reaction to gadolinium contrast agents; thus, a known allergy to gadolinium contrast. * Subject who, based on the physician's judgment, may be at increased risk for complications associated with renal function, anticoagulant therapy, or bleeding disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast screening are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Solis Mammography Memorial Village
Houston, Texas, 77024, United States
-
Washington Radiology Sterling
Sterling, Virginia, 20166, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.